//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
Open access link to early results of CAR-T trial: LBS1:02 CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, obecabtagene autoleucel (obe-cel), in severe refractory systemic lupus erythematosus (srSLE): initial results from phase I CARLYSLE study 🧪💉 lupus.bmj.com/content/13/S...
1d
Objectives To report initial safety, efficacy, pharmacokinetics (PK) and biomarker analyses in patients with srSLE, treated with obe-cel in the ongoing open-label CARLYSLE study ( NCT06333483).Methods...
lupus.bmj.com
LBS1:02 CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, obecabtagene autoleucel (obe-cel), in severe refractory systemic lupus erythematosus (srSLE): initial results from phase I CARLYS...
Dan Jagger